Avanir Pharmaceuticals, Inc.
) recently received approval for Nuedexta in the EU for the
treatment of patients suffering from pseudobulbar affect
The marketing application was based on controlled phase III
studies of Nuedexta in patients with PBA, plus data from
longer-term safety studies. The EU approval was expected as, in
Apr 2013, Avanir had received a positive opinion from the
Committee for Medicinal Products for Human Use (CHMP) for
We note that Nuedexta was launched in the US in Jan 2011 for
the treatment of PBA. Net Nuedexta revenues grew 11% sequentially
to $16.5 million in the second quarter of fiscal 2013.
We are encouraged by Avanir's progress on its pipeline.
Nuedexta is being studied for three additional indications,
namely, agitation in Alzheimer's disease (phase II ongoing),
central neuropathic pain in multiple sclerosis (phase II ongoing)
and levodopa-induced-dyskinesia in Parkinson's disease
(enrollment for phase II about to begin). Avanir plans to
accelerate the PRIME study on Nuedexta for the neuropathic pain
related to multiple sclerosis indication. Top-line data from the
study is expected in the fourth quarter of 2013.
Earlier this month, Avanir had held a pre-IND (Investigational
New Drug) meeting with the US Food and Drug Administration (FDA)
for AVP-786. AVP-786 is being developed for the treatment of
neurologic and psychiatric disorders. Following interactions with
the FDA, an agreement was reached for a faster development path
for Avanir's AVP-786.
Under the agreement with the FDA, Avanir will be allowed to
use the data generated on Nuedexta to support the IND application
as well as regulatory filings for AVP-786 in the US. This will
not only help fasten the development process for AVP-786, it will
also lower development-related costs.
Avanir currently carries a Zacks Rank #3 (Hold). Currently,
Jazz Pharmaceuticals Public Limited Company
Salix Pharmaceuticals Ltd.
) look well positioned with a Zacks Rank #1 (Strong Buy).
AVANIR PHARM (AVNR): Free Stock Analysis
JAZZ PHARMACEUT (JAZZ): Free Stock Analysis
SALIX PHARM-LTD (SLXP): Free Stock Analysis
SANTARUS INC (SNTS): Free Stock Analysis
To read this article on Zacks.com click here.